Warangal, India
Warangal, India

Time filter

Source Type

Singh S.P.,NIMS University | Bharti V.,NIMS University | Singh B.M.K.,DCE Inc | Johri P.,GIMT | Sharma M.,DCE Inc
Proceeding - IEEE International Conference on Computing, Communication and Automation, ICCCA 2016 | Year: 2016

Internet Protocol Security (IPSec) is a standard suite of protocols defined by Internet Engineering Task Force (IETF) to provide security which includes data authentication, integrity, and confidentiality. IPSec provides data security at the IP packet level. IPSec developed for IPv6 as well as for IPv4. IPSec protocol provides an elegant solution to the security problem of IP protocol, at IP layer itself. Due to the features of IPSec protocol it is widely used protocol to secure IP packets. IPSec is an end-to-end security scheme operating in the Internet Layer of the Internet Protocol Suite, while some other Internet security systems in widespread use, such as Transport Layer Security (TLS) and Secure Shell (SSH), operate in the upper layers at Application layer. Hence, only IPSec protects any application traffic over an IP network. A security association is used to create a secure channel. The security association depends on the requirement of the communicating parties, which is actually the aspect of security desired. All the security associations can be stored in a database. The database is called the Security Association Database (SAD). The security association database can be understood as a two-dimensional table with each row defining a single SA. © 2016 IEEE.


News Article | May 22, 2017
Site: www.businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a request for additional information (“Second Request”) from the United States Federal Trade Commission (FTC) in connection with the pending acquisition of CTP-656 and other assets related to the treatment of cystic fibrosis by Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). The Second Request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act). Concert intends to work cooperatively with the FTC as it reviews the transaction. As announced on March 6, 2017, pursuant to an asset purchase agreement, Vertex will pay Concert $160 million in cash for all worldwide development and commercialization rights to CTP-656 and Concert’s other cystic fibrosis assets. If CTP-656 is approved as part of a combination regimen to treat CF, Concert could receive up to an additional $90 million in milestones based on regulatory approval in the U.S. and agreement for reimbursement in the first of the United Kingdom, Germany or France. Concert’s annual meeting of stockholders will be held on May 24, 2017 at 9:00 a.m. and will include for consideration the authorization of the CTP-656 asset purchase agreement. Concert’s Board of Directors unanimously supports the transaction and recommends that Concert’s shareholders vote in favor of it. Concert continues to expect the transaction to close by October 31, 2017. Additional Information about the Transaction and Where to Find It This press release is being made in respect of the proposed asset sale with Vertex. The proposed asset sale and the asset purchase agreement has been submitted to the shareholders of Concert for their consideration and approval pursuant to a definitive proxy statement filed with the Securities and Exchange Commission (SEC) on April 26, 2017. This press release does not constitute a solicitation of any vote or proxy from any shareholder of Concert. Investors are urged to read the proxy statement carefully and in its entirety and any other relevant documents or materials filed or to be filed with the SEC or incorporated by reference in the proxy statement, because they contain or will contain important information about the proposed asset sale. The definitive proxy statement has been mailed to Concert’s shareholders. In addition, the proxy statement and other documents are available free of charge at the SEC’s internet website, www.sec.gov. The proxy statement and other pertinent documents may also be obtained free of charge at the Investors section of Concert’s website, www.concertpharma.com, or by directing a written request to Concert Pharmaceuticals, Inc., Attn: Investor Relations, at 99 Hayden Ave, #500, Lexington, MA 02421. Concert and its directors, executive officers and other members of management, and employees, may be deemed to be participants in the solicitation of proxies in connection with the proposed asset sale. Information about Concert’s directors and executive officers and their interests in the transaction are included in Concert’s Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 6, 2017, the definitive proxy statement filed with the SEC on April 26, 2017 and all additional proxy soliciting materials filed with the SEC. These documents can be obtained free of charge from the sources indicated above. About Concert Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company’s approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com. Cautionary Note on Forward Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements about the asset purchase agreement, potential payments to be received pursuant to the asset purchase agreement, the expected timing of the closing of the transaction and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the possibility that the closing conditions to the contemplated transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, place conditions on, or refuse to grant a necessary regulatory approval; the occurrence of any event that could give rise to termination of the asset purchase agreement; the risk that the proposed transaction disrupts current plans and operations, increases operating costs, results in management distraction and the potential difficulties in maintaining relationships with customers, suppliers and other third parties and employee retention as a result of the transaction and additional regulatory authority requests; the uncertainties inherent in the initiation of future clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials; expectations for regulatory approvals; availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other factors discussed in the “Risk Factors” section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release. Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.


News Article | May 17, 2017
Site: www.businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that its CTP-543 Phase 2a clinical trial for alopecia areata has been placed on clinical hold. The FDA had previously informed the Company that it could initiate the Phase 2a clinical trial; however, subsequent to its initiation, but prior to dosing subjects, the FDA informed the Company that a review of certain recently completed non-clinical toxicology studies is required before proceeding. The FDA did not cite a safety concern; however, they intend to review these additional non-clinical data as support for the one-year dosing duration as planned in the Phase 2a trial. At the request of the FDA, the Company intends to submit the requested non-clinical study reports promptly. By regulation, the FDA has 30 days from receipt of Concert’s response to notify the company whether the clinical hold is lifted. Concert is working diligently with the FDA to resume enrollment in the Phase 2a trial as quickly as possible. About CTP-543 and Alopecia Areata CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib, a drug which selectively inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially available under the name Jakafi in the United States for the treatment of certain blood disorders. Ruxolitinib has been used to treat alopecia areata in academic settings, including an investigator-sponsored clinical trial, and has been reported to promote hair growth in individuals with moderate-to-severe disease. Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of alopecia areata. About Concert Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company’s approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com. Cautionary Note on Forward Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements about our expectations on the clinical development of CTP-543, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals and other factors discussed in the "Risk Factors" section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release. 1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403. Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc. Jakafi® is a registered trademark of Incyte Corporation.


LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that in connection with its annual shareholder meeting, Concert shareholders voted to approve the asset purchase agreement under which Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) will acquire CTP-656 and other assets related to the treatment of cystic fibrosis. CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis. The companies entered into the asset purchase agreement on March 3, 2017. The shareholder approval satisfies one of the conditions to the closing of the asset purchase agreement. Closing of the transaction remains subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Concert continues to expect the transaction to close by October 31, 2017. As part of the agreement, Vertex will pay Concert $160 million in cash for all worldwide development and commercialization rights to CTP-656. If CTP-656 is approved as part of a combination regimen to treat cystic fibrosis, Concert could receive up to an additional $90 million in milestones based on regulatory approval in the U.S. and reimbursement in the UK, Germany or France. “We would like to express our appreciation to Concert’s shareholders for their support. We believe this transaction provides the best path to advance CTP-656 as a treatment for cystic fibrosis patients, and provides financial strength to enable Concert to advance our proprietary pipeline of innovative medicines,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company’s approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com. Any statements in this press release about our future expectations, plans and prospects, including statements about the potential payments to be received pursuant to the asset purchase agreement, the expected timing of the closing of the transaction clinical development of CTP-656 and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the possibility that the closing conditions to the contemplated transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, place conditions on, or refuse to grant a necessary regulatory approval; the occurrence of any event that could give rise to termination of the asset purchase agreement; the risk that the proposed transaction disrupts current plans and operations, increases operating costs, results in management distraction and the potential difficulties in maintaining relationships with customers, suppliers and other third parties and employee retention as a result of the transaction and additional regulatory authority requests; the uncertainties inherent in the initiation of future clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials; expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release. Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.


New York, NY, May 01, 2017 --( The full report can be found here: Highlights From Report Include: Thunder Energy has already filed 2 grant applications with the Defense Threat Reduction Agency of the Department of Defense to develop nuclear weapon detection stations. The company has completed all the federal procurement requirements and is expected to get a $9 million grant once the application has been approved. The Santilli Telescope™ designed by Thunder Energy is the only existing telescope which can detect anti-matter light in deep space through its special concave lens. Thunder Energies was granted a $53,000 promissory initial funding from a New York investment banking group, the Power Up Group. The note will be fully converted into stock on December 14, 2017. The funds will be used for the development of nuclear weapon detection stations. Full disclosures pertaining to this report can be found at http://smallcapdigital.com/digital-marketing-services/equity-research-reports/. Thunder Energies has paid for this report as company sponsored research, which is meant to subsidize the high cost of creating the report and monitoring the security. About Thunder Energies Corporation: Thunder Energies Corporation is a development stage company, previously incorporated formally as Thunder Fusion Corporation. The company’s primary focus is its Division of Nuclear Equipment (DNE), which provides new technologies to detect smuggled nuclear weapons using a novel synthesis of the neutron from a hydrogen gas. The other two divisions are Combustion Equipment (DCE) and Optical Equipment (DOE), DCE is working on the novel HyperFurnace which achieves the full combustion of fossil fuels and DOE is engaged in the production and sale of 50 mm to 200 mm pairs of Galileo and Santilli telescopes, which are projected to generate millions in sales and support the company’s longer term goals. The technologies of the three divisions are protected by individual patent applications fully owned without royalties by Thunder Energies Corporation. More information on Thunder Energies can be found at http://thunder-energies.com/. About Small Cap Digital: Small Cap Digital is a digital marketing agency that specializes in utilizing the latest technologies to build organic, engaged audiences for nano, micro and small cap public companies. We create viral content for your product or service and build active digital marketing channels to strategically distribute and amplify this content. New York, NY, May 01, 2017 --( PR.com )-- Small Cap Digital, a leading digital marketing agency specializing in micro cap and small cap companies, has announced it has released an initiation report on Thunder Energies Corporation (OTC: TNRG).The full report can be found here: Thunder Energies Initiation Highlights From Report Include:Thunder Energy has already filed 2 grant applications with the Defense Threat Reduction Agency of the Department of Defense to develop nuclear weapon detection stations. The company has completed all the federal procurement requirements and is expected to get a $9 million grant once the application has been approved.The Santilli Telescope™ designed by Thunder Energy is the only existing telescope which can detect anti-matter light in deep space through its special concave lens.Thunder Energies was granted a $53,000 promissory initial funding from a New York investment banking group, the Power Up Group. The note will be fully converted into stock on December 14, 2017. The funds will be used for the development of nuclear weapon detection stations.Full disclosures pertaining to this report can be found at http://smallcapdigital.com/digital-marketing-services/equity-research-reports/. Thunder Energies has paid for this report as company sponsored research, which is meant to subsidize the high cost of creating the report and monitoring the security.About Thunder Energies Corporation:Thunder Energies Corporation is a development stage company, previously incorporated formally as Thunder Fusion Corporation. The company’s primary focus is its Division of Nuclear Equipment (DNE), which provides new technologies to detect smuggled nuclear weapons using a novel synthesis of the neutron from a hydrogen gas. The other two divisions are Combustion Equipment (DCE) and Optical Equipment (DOE), DCE is working on the novel HyperFurnace which achieves the full combustion of fossil fuels and DOE is engaged in the production and sale of 50 mm to 200 mm pairs of Galileo and Santilli telescopes, which are projected to generate millions in sales and support the company’s longer term goals. The technologies of the three divisions are protected by individual patent applications fully owned without royalties by Thunder Energies Corporation. More information on Thunder Energies can be found at http://thunder-energies.com/.About Small Cap Digital:Small Cap Digital is a digital marketing agency that specializes in utilizing the latest technologies to build organic, engaged audiences for nano, micro and small cap public companies. We create viral content for your product or service and build active digital marketing channels to strategically distribute and amplify this content. Click here to view the list of recent Press Releases from JGR Capital


Narayan Y.,DCE Inc
Proceedings - 2013 International Conference on Emerging Trends in Communication, Control, Signal Processing and Computing Applications, IEEE-C2SPCA 2013 | Year: 2013

In This paper we discussed about Networked control systems (NCS) for controlling flow rate of two non-interacting tank processes using fuzzy logic controller. Basically NCS are used for network communication to enable exchange of information of plant response via communication channel. For controlling the flow rate of processes we use fuzzy logic controller with a network on a shared medium to connect plant & controller. The experimental application of NCS in this paper work is manufacturing plant monitoring to provide decision & command, factory automation © 2013 IEEE.


Roy P.K.,Center for Fire | Swami V.,DCE Inc | Kumar D.,DCE Inc | Rajagopal C.,Center for Fire
Journal of Applied Polymer Science | Year: 2011

Because of the presence of carboxylic acid moieties, poly(acrylic acid) possesses a unique ability to form stable complexes with divalent metal ions. However, its practical use for the removal of heavy metals from aqueous solutions is restricted because of its inherent water solubility. To address this issue, crosslinking of this polymer has been attempted to synthesize hydrogel, which is stable in aqueous medium over a wide range of pH values. The hydrogels, prepared by redox polymerization of acrylic acid in the presence of polyethylene glycol diacrylate as the crosslinker, were characterized by Fourier transform infrared spectrometry, elemental analysis, thermal analysis, and swelling studies. This chelating hydrogel-bearing O, O donor groups exhibited high-metal sorption capacity of 41.1, 58.2, 43.1, and 81.2 mg/g for Cr 6+, Ni2+, Cu2+, and Pb2+, respectively, under optimum conditions. The effect of parameters including pH, concentration, and interference of common ions on metal uptake was also investigated. Langmuir and Freundlich adsorption isotherms have been used to validate the metal uptake data. High recovery (>97%) was achievable for all metal ions with 1N HCl as eluting agent, and the regeneration tests revealed that the sorbent could be used repeatedly for at least 10 cycles without any loss in chelating efficiency. © 2011 Wiley Periodicals, Inc..


Xiang Y.,University of Lille Nord de France | Xiang Y.,DCE Inc | Delbarre H.,University of Lille Nord de France | Sauvage S.,University of Lille Nord de France | And 7 more authors.
Environmental Pollution | Year: 2012

During summer 2009, online measurements of 25 Volatile Organic Compounds (VOCs) from C6 to C10 as well as micro-meteorological parameters were simultaneously performed in the industrial city of Dunkerque. With the obtained data set, we developed a methodology to examine how the contributions of different source categories depend on atmospheric turbulences, and the results provided identification of emission modes. Eight factors were resolved by using Positive Matrix Factorization model and three of them were associated with mixed sources. The observed behaviours of contributions with turbulences lead to attribute some factors with sources at ground level, and some other factors with sources in the upper part of surface layer. The impact of vertical turbulence on the pollutant dispersion is also affected by the distance between sources and receptor site. © 2011 Elsevier Ltd. All rights reserved.


Mazumder S.K.,DCE Inc
ISH Journal of Hydraulic Engineering | Year: 2016

Estimation of scour in bridge piers is necessary for economic and safe design of bridges. Although a large number of mathematical models are available, scour estimation in Indian bridges is done by empirical equation like Lacey in both fine and coarse soil. Total scour depths in piers, founded on fine soil, are estimated in five bridges in India using different mathematical models and are compared with those found by IRC method based on Lacey’s theory. IRC method is found to overestimate scour in all the cases and the error is found to vary between 5 and 275%. Local scour depths in bridge piers founded on coarse soil are observed at five bridge sites in Mississippi river basin in U.S.A. Scour depths observed are compared with those predicted by different mathematical models and also by IRC method. Compared to IRC method, scour in piers founded on coarse soil, governed both by size and gradation of sediments, is found to be significantly less than that in fine uniform soil under all velocity of flow. It is observed that the scour depths predicted by mathematical models are quite conservative and closer to the observed ones. © 2016 Indian Society for Hydraulics


Dce

Trademark
DCE Inc | Date: 2011-10-13

wiring harnesses for control, monitoring and protection of vehicle electrical systems including gasoline and diesel engines; electronic power steering units for land vehicles and watercraft.

Loading DCE Inc collaborators
Loading DCE Inc collaborators